Can serum lipid and CRP levels predict the "severity" of aortic valve stenosis?

Acta Cardiologica

Volumn 58, Issue 4, 2003, Pages 321-326

  Gunduz, Huseyin ^a   Akdemir, Ramazan ^a   Binak, Emrah ^a   Tamer, Ali ^a   Keser, Nurgul ^a   Uyan, Cihangir ^a  

^a Bahçeelievler Mah ^*

Author keywords

Aortic stenosis; CRP; Hyperlipidaemia

Indexed keywords

C REACTIVE PROTEIN; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGED; AORTA VALVE STENOSIS; ARTERY CALCIFICATION; ARTICLE; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIPID STORAGE; MAJOR CLINICAL STUDY; MALE; PREDICTION; RISK BENEFIT ANALYSIS;

AGED; AORTIC VALVE STENOSIS; C-REACTIVE PROTEIN; CHOLESTEROL; DISEASE PROGRESSION; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HUMANS; MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 0042065337     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.58.4.2005289     Document Type: Article

References (36)

1. Wilmshurst PT, Stevenson RN, Griffiths H, Lord JR. A case-control investigation of the relation between hyperlipidaemia and calcific aortic valve stenosis. Heart. 1997 Nov; 78: 475-9.
2. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, Kitzman DW, Otto CM. Clinical factors associated with calcific aortic valve disease. J Am Coll Cardiol 1997; 29: 630-4.
3. Lindroos M, Kupari M, Heikkila J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol 1993; 21: 1220-5.
4. Davies MJ. Pathology of aortic stenosis in the elderly. Cardiol Elderly 1995; 3: 161-5.
5. Davies MJ, Treasure T, Parker DJ. Demographic characteristics of patients undergoing aortic valve replacement for stenosis: relation to valve morphology. Heart 1996; 75: 174-8.
6. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD. Characterization of the early lesions of "degenerative" valvular aortic stenosis. Circulation 1994; 90: 844-53.
7. Olsson M. Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 1999; 19: 1218-22.
8. Nassimiha D, Aronow WS, Ahn C, Goldman ME. Asssociation of coronary risk factors with progression of valvular aortic stenosis in older persons. Am J Cardiol 2001; 87: 1313-4.
9. Boon A, Cheriex E, Lodder J, Kessel F. Cardiac valve calcification: characteristics of patients with calcification of the mitral annulus or aortic valve. Heart. 1997 Nov; 78: 472-4.
10. Mohler ER, Sheridan MJ, Nichols R, Harvey WP, Waller BF. Development and progression of aortic valve stenosis: atherosclerosis risk factors - a causal relationship? A clinical morphologic study. Clin Cardiol. 1991 Dec; 14: 995-9.
11. Aronow WS, Schwartz KS, Koenigsberg M. Correlation of serum lipids, calcium, and phosphorus, diabetes mellitus and history of systemic hyper-tension with presence or absence of calcified or thickened aortic cusps or root in elderly patients. Am J Cardiol 1987; 59: 998-9.
12. Mautner GC, Roberts WC. Reported frequency of coronary arterial narrowing by angiogram in patients with valvular aortic stenosis. Am J Cardiol 1992; 70: 539-40.
13. Agmon Y, Bijoy K, Khandheria FA, Meissner I. Aortic valve sclerosis and aortic atherosclerosis: different manifestations of the same disease? Insight from a population-based study. J Am Coll Cardiol 2001; 38: 827-34.
14. Novaro GM, Pearce GL, Sprecher DL, Griffin BP. Comparison of cardiovascular risk and lipid profiles in patient undergoing aortic valve surgery versus those undergoing coronary artery bypass grafting. J Heart Valve Dis 2001; 10: 19-24.
15. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994; 344: 1383-9.
16. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995; 333: 1301-7.
17. Peter M, Hoffman A, Parker C, Luscher T, Burckhardt D. Progression of aortic stenosis. Role of age and concomitant coronary artery disease. Chest 1993; 103: 1715-9.
18. Mautner GC, Mautner SL, Cannon RO, Hunsberg SA, Roberts WC. Clinical factors useful in predicting aortic valve structure in patients >40 years of age with isolated valvular aortic stenosis. Am J Cardiol 1993; 72: 194-8.
19. Deutscher S, Rockette HE, Krishnaswami V. Diabetes and hypercholesterolemia among patients with calcific aortic stenosis. Am J Cardiol 1985 1; 55: 744-7.
20. Rallidis L, Nihoyannopoulos P, Thompson GR. Aortic ste-nosis in homozygous familial hypercholesterolaemia. Heart 1996; 76: 84-5.
21. Hoagland PM, Cook EF, Flatley M, Walker C, Goldman L. Case-control analysis of risk factors for presence of aortic stenosis in adults (age 50 years or older). Am J Cardiol 1985; 55: 744-7.
22. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333: 1301-7.
23. Galante A, Pietroiusti A, Vellini M, Piccolo P, Possati G, De Bonis M, Grillo RL, Fonana C, Favalli C. C-reactive protein is increased in patients with degenerative aortic valvular stenosis. J Am Coll Cardiol 2001; 38: 1078-82.
24. Pepys MB, Berger A. The renaissance of C reactive protein. BMJ 2001; 322: 4-5.
25. Blackburn R, Giral P, Bruckert E, Andre JM, Gonbert S, Bernard M, Chapman MJ, Turpin G. Elevated C-reactive protein constitutes an independent predictor of advanced carotid paques in dyslipidemic subjects. Arteroscler Thromb Vasc Biol 2001; 21(12): 1962-8.
26. Bhakdi S, Torzewski M, Klouche M, Hemmes M. Complement and atherogenesis. Binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 1999; 19: 2348-54.
27. Zhang YX, Cliff WJ, Schoefl GI, Higgins G. Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis 1999; 145: 375-9.
28. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513-20.
29. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999; 100: 230-5.
30. Haverkate F, Thompson SG, Pyke SDM, Gallimore IR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997; 349: 462-6.
31. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994 Aug 18; 331(7): 417-24.
32. Buffon A, Liuzzo G, Biasucci LM, Pasqualetti P, Ramazzotti V, Rebuzzi AG, Crea F, Maseri A. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol. 1999 Nov 1; 34: 1512-21.
33. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflam-mation, aspirin.and the risk of cardiovascular disease in apparently healthy men (Published erratum appears in N Engl J Med 1997; 337: 356). N Engl J Med 1997; 336: 973-9.
34. Berk BC, Weintnaub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol 1990; 65: 168-72.
35. de Beer FC, Hind CR, Poa KM, AlIan KM, Maseni A, Pepys MB. Measure-ment of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J 1982: 47: 239-43.
36. Rader DJ. Inflammatory markers of coronary risk. N Engl J Med 2000; 343: 1179-82.